GERN
Geron CorporationNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.11B
P/E Ratio
—
EPS
$-0.13
Beta
0.67
52W High
$2.01
52W Low
$1.04
50-Day MA
$1.58
200-Day MA
$1.38
Dividend Yield
—
Profit Margin
-45.40%
Forward P/E
—
PEG Ratio
-2.38
About Geron Corporation
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
Fundamentals
| Revenue (TTM) | $183.88M |
| Gross Profit (TTM) | $179.14M |
| EBITDA | $-51.08M |
| Operating Margin | -17.70% |
| Return on Equity | -33.00% |
| Return on Assets | -5.54% |
| Revenue/Share (TTM) | $0.28 |
| Book Value | $0.35 |
| Price-to-Book | 4.72 |
| Price-to-Sales (TTM) | 6.06 |
| EV/Revenue | 4.517 |
| EV/EBITDA | -9.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 1.00% |
| Shares Outstanding | $640.54M |
| Float | $510.71M |
| % Insiders | 0.10% |
| % Institutions | 77.95% |
Analyst Ratings
Consensus ($3.40 target)
1
Strong Buy3
Buy1
Hold1
SellData last updated: 4/8/2026